Core Viewpoint - Sprinklr (CXM) shows potential for upside with a mean price target of $10.5, indicating a 32.9% increase from its current price of $7.9, following a 5.1% gain over the past four weeks [1]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.12, suggesting variability in analyst predictions. The lowest estimate is $8.00 (1.3% increase), while the highest is $17.00 (115.2% increase) [2]. - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about CXM's earnings prospects, with a strong consensus on revising EPS estimates higher, which correlates with potential stock price increases [11]. - The Zacks Consensus Estimate for the current year has risen by 6.8% over the past month, with two estimates increasing and no negative revisions [12]. - CXM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set unbiased targets has been questioned [3]. - Price targets can often mislead investors, and while they should not be ignored, they should be approached with skepticism [10].

Profound Medical (PROF) closed the last trading session at $6.75, gaining 15.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.31 indicates an 82.4% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $2.01. While the lowest estimate of $11.00 indicates a 63% increase from the current price level, the most optimistic analyst ...

Shares of Theravance Biopharma (TBPH) have gained 25.8% over the past four weeks to close the last trading session at $18.7, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $24.43 indicates a potential upside of 30.6%.The mean estimate comprises seven short-term price targets with a standard deviation of $8.85. While the lowest estimate of $13.00 indicates a 30.5% decline from t ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on DXP Enterprises (DXPE), and emphasizes the importance of using these recommendations in conjunction with other research tools like the Zacks Rank to make informed investment decisions [1][5][11]. Brokerage Recommendations - DXP Enterprises has an average brokerage recommendation (ABR) of 1.83, indicating a consensus between Strong Buy and Buy, with one Strong Buy and one Buy recommendation from three brokerage firms [2][5]. - The distribution of recommendations shows that Strong Buy and Buy each account for 33.3% of the total recommendations [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential, often reflecting a strong positive bias due to the vested interests of brokerage firms [5][6][11]. - Analysts tend to issue more favorable ratings than their research would support, which can mislead investors [11]. Zacks Rank as an Alternative - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, based on earnings estimate revisions, and is classified into five groups from Strong Buy to Strong Sell [8][12]. - The Zacks Rank is updated more frequently than the ABR, making it a timely tool for predicting future stock prices [13]. Current Earnings Estimates for DXP Enterprises - The Zacks Consensus Estimate for DXP Enterprises remains unchanged at $4.75 for the current year, suggesting steady analyst views on the company's earnings prospects [14]. - The unchanged consensus estimate has resulted in a Zacks Rank of 3 (Hold) for DXP Enterprises, indicating a cautious approach despite the Buy-equivalent ABR [15].

Shares of SSR Mining (SSRM) have gained 10.1% over the past four weeks to close the last trading session at $21.44, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.23 indicates a potential upside of 27%.The mean estimate comprises 10 short-term price targets with a standard deviation of $4.63. While the lowest estimate of $18.70 indicates a 12.8% decline from the current pri ...

Core Viewpoint - Fiverr International (FVRR) has shown a 4.4% gain over the past four weeks, with a mean price target of $31.9 indicating a potential upside of 48.6% from the current price of $21.47 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $4.98, where the lowest estimate is $25.00 (16.4% increase) and the highest is $44.00 (104.9% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about FVRR's earnings prospects, with a positive trend in earnings estimate revisions indicating potential upside [4][11] - Over the last 30 days, two earnings estimates have been revised higher, leading to a 20% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - FVRR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for potential price movement [14]

Core Viewpoint - Biohaven Ltd. (BHVN) shows significant potential for upside, with a mean price target of $20.75 indicating a 127.5% increase from its current price of $9.12, reflecting strong analyst optimism about the company's earnings prospects [1][11]. Price Targets and Analyst Consensus - The average price target for BHVN is based on 16 estimates, ranging from a low of $9.00 to a high of $50.00, with a standard deviation of $12.14, indicating variability in analyst predictions [2]. - The lowest estimate suggests a minor decline of 1.3%, while the highest estimate indicates a potential upside of 448.3% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Revisions - Analysts have shown increasing optimism about BHVN's earnings, with eight estimates revised higher in the last 30 days and no negative revisions, leading to a 5.9% increase in the Zacks Consensus Estimate [12][11]. - The company holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements accurately [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Core Viewpoint - Grindr Inc. (GRND) shares have increased by 2.4% over the past four weeks, closing at $13.51, with a mean price target of $21.75 indicating a potential upside of 61% [1] Price Targets - The average price target consists of four estimates ranging from a low of $20.00 to a high of $26.00, with a standard deviation of $2.87, suggesting a potential increase of 48% to 92.5% from the current price [2] - A low standard deviation indicates a strong agreement among analysts regarding the price targets, which can be a useful indicator for further research [9] Analyst Sentiment - Analysts have shown increasing optimism about GRND's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 12.8% over the past month, with no negative revisions [12] Zacks Rank - GRND holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Sandoz Group AG Sponsored ADR (SDZNY) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system focuses on changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For Sandoz Group AG, the recent increase in earnings estimates and the upgrade in rating suggest an improvement in the company's underlying business, likely leading to a rise in stock price [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Sandoz Group AG is expected to earn $3.26 per share, which remains unchanged from the previous year, but the Zacks Consensus Estimate has increased by 2.3% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Sandoz Group AG to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - IdaCorp (IDA) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - For the fiscal year ending December 2025, IdaCorp is expected to earn $5.85 per share, with a 0.2% increase in the Zacks Consensus Estimate over the past three months [8]. Investment Implications - The upgrade reflects an improvement in IdaCorp's underlying business, suggesting that investor sentiment may lead to increased stock prices [5][10]. - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, indicating a strong potential for market-beating returns [9][10].